Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting
up to 5% of the population. VTE commonly manifests as lower-extremity deep venous …

D-dimer is a fibrin degradation product encompassing multiple cross-linked D domains
and/or E domains present in the original fibrinogen molecule, whose generation is only …

Background Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major
trials focusing on the clinical benefits of catheter-directed treatment, heparin …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Background Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure
present in around 25% of adults. In most cases, PFO is entirely benign and requires no …

Importance The optimal treatment of intermediate-high–risk pulmonary embolism (PE)
remains unknown. Objective To assess the effect of conventional catheter-directed …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …

The term heparin resistance (HR) is used by clinicians without specific criteria. We
performed a literature search and surveyed our SSC membership to better define the term …

Clinicians have been more and more often encountering patients with venous
thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, leading …

Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent
recurrent VTE and death, which exposes them to an inherent increased risk of bleeding …